These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 15010837)

  • 1. HER2/neu-derived peptides recognized by both cellular and humoral immune systems in HLA-A2+ cancer patients.
    Ishihara Y; Harada M; Azuma K; Tamura M; Shomura H; Fujii T; Itoh K; Shichijo S
    Int J Oncol; 2004 Apr; 24(4):967-75. PubMed ID: 15010837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes.
    Kono K; Rongcun Y; Charo J; Ichihara F; Celis E; Sette A; Appella E; Sekikawa T; Matsumoto Y; Kiessling R
    Int J Cancer; 1998 Oct; 78(2):202-8. PubMed ID: 9754653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes.
    Peiper M; Goedegebuure PS; Linehan DC; Ganguly E; Douville CC; Eberlein TJ
    Eur J Immunol; 1997 May; 27(5):1115-23. PubMed ID: 9174600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural CD8+ T-cell responses against MHC class I epitopes of the HER-2/ neu oncoprotein in patients with epithelial tumors.
    Sotiropoulou PA; Perez SA; Voelter V; Echner H; Missitzis I; Tsavaris NB; Papamichail M; Baxevanis CN
    Cancer Immunol Immunother; 2003 Dec; 52(12):771-9. PubMed ID: 13680193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modification of the HER2/NEU-derived tumor antigen GP2 improves induction of GP2-reactive cytotoxic T lymphocytes.
    Tanaka Y; Amos KD; Joo HG; Eberlein TJ; Goedegebuure PS
    Int J Cancer; 2001 Nov; 94(4):540-4. PubMed ID: 11745441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2(+) patients with hormone-refractory prostate cancer.
    Matsueda S; Kobayashi K; Nonaka Y; Noguchi M; Itoh K; Harada M
    Cancer Immunol Immunother; 2004 Jun; 53(6):479-89. PubMed ID: 14634796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
    Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W
    Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of HER2/ neu-derived peptides capable of inducing both cellular and humoral immune responses in HLA-A24 positive breast cancer patients.
    Azuma K; Shichijo S; Shomura H; Matsueda S; Fujii T; Itoh K
    Breast Cancer Res Treat; 2004 Jul; 86(1):19-29. PubMed ID: 15218358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
    Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J
    Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
    Seliger B; Rongcun Y; Atkins D; Hammers S; Huber C; Störkel S; Kiessling R
    Int J Cancer; 2000 Aug; 87(3):349-59. PubMed ID: 10897039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer.
    Yoshino I; Goedegebuure PS; Peoples GE; Parikh AS; DiMaio JM; Lyerly HK; Gazdar AF; Eberlein TJ
    Cancer Res; 1994 Jul; 54(13):3387-90. PubMed ID: 7912166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu-Expressing Tumor in HLA-A2 Transgenic Mice.
    Tran T; Diniz MO; Dransart E; Gey A; Merillon N; Lone YC; Godefroy S; Sibley C; Ferreira LC; Medioni J; Oudard S; Johannes L; Tartour E
    Clin Cancer Res; 2016 Aug; 22(16):4133-44. PubMed ID: 27006496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of peptide-specific cytotoxic T lymphocytes using allogeneic dendritic cells capable of lysing human pancreatic cancer cells.
    Peiper M; Goedegebuure PS; Eberlein TJ
    Surgery; 1997 Aug; 122(2):235-41; discussion 241-2. PubMed ID: 9288128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas.
    Rongcun Y; Salazar-Onfray F; Charo J; Malmberg KJ; Evrin K; Maes H; Kono K; Hising C; Petersson M; Larsson O; Lan L; Appella E; Sette A; Celis E; Kiessling R
    J Immunol; 1999 Jul; 163(2):1037-44. PubMed ID: 10395702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterologous human/rat HER2-specific exosome-targeted T cell vaccine stimulates potent humoral and CTL responses leading to enhanced circumvention of HER2 tolerance in double transgenic HLA-A2/HER2 mice.
    Xie Y; Wu J; Xu A; Ahmeqd S; Sami A; Chibbar R; Freywald A; Zheng C; Xiang J
    Vaccine; 2018 Mar; 36(11):1414-1422. PubMed ID: 29415817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer.
    Linehan DC; Goedegebuure PS; Peoples GE; Rogers SO; Eberlein TJ
    J Immunol; 1995 Nov; 155(9):4486-91. PubMed ID: 7594611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer.
    Yoshino I; Peoples GE; Goedegebuure PS; Maziarz R; Eberlein TJ
    J Immunol; 1994 Mar; 152(5):2393-400. PubMed ID: 8133050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pancreatic cancer associated ascites-derived CTL recognize a nine-amino-acid peptide GP2 derived from HER2/neu.
    Peiper M; Goedegebuure PS; Izbicki JR; Eberlein TJ
    Anticancer Res; 1999; 19(4A):2471-5. PubMed ID: 10470176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct measurement of peptide-specific CD8+ T cells using HLA-A2:Ig dimer for monitoring the in vivo immune response to a HER2/neu vaccine in breast and prostate cancer patients.
    Woll MM; Fisher CM; Ryan GB; Gurney JM; Storrer CE; Ioannides CG; Shriver CD; Moul JW; McLeod DG; Ponniah S; Peoples GE
    J Clin Immunol; 2004 Jul; 24(4):449-61. PubMed ID: 15163902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TCR V beta 3+ and V beta 6+ CTL recognize tumor-associated antigens related to HER2/neu expression in HLA-A2+ ovarian cancers.
    Peoples GE; Yoshino I; Douville CC; Andrews JV; Goedegebuure PS; Eberlein TJ
    J Immunol; 1994 May; 152(10):4993-9. PubMed ID: 7909829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.